Tirzepatide on TikTok: separating real data from hype

What did @natashawakefield1 actually say?

The creator compared two GLP-1 related drugs, referring to retatrutide as "Ratatouille" and tirzepatide as "Mungara" throughout the video. The core claims were: retatrutide burns more calories through increased energy expenditure without added exercise, retatrutide does not reduce food noise while tirzepatide does, and the muscle-retention edge seen with retatrutide in trials comes down to one simple thing: people can still eat enough protein on it. These are actually interesting mechanistic claims, and they are not entirely wrong. But the mangled drug names and some oversimplifications are worth unpacking carefully before anyone acts on this information.

Does the science back this up?

Partly, yes. Retatrutide is a triple agonist, hitting GIP, GLP-1, and glucagon receptors simultaneously. That glucagon component is the key piece the creator is gesturing at. Glucagon receptor activation does increase resting energy expenditure, and this is supported by the Phase 2 retatrutide trial (Jastreboff et al., 2023, New England Journal of Medicine), which showed up to 24.2% body weight reduction over 48 weeks, a result that outpaced tirzepatide's Phase 3 numbers. The energy expenditure angle has mechanistic plausibility. Tirzepatide is a dual GIP/GLP-1 agonist and its appetite-suppressing effects are well documented in the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM). The claim that tirzepatide more aggressively quiets food noise than retatrutide is plausible but has not been tested head-to-head in a published trial. The creator is extrapolating from mechanism and anecdote, which is honest in a biohacking context but should be labeled as such.

What did they get wrong (or right)?

The muscle retention claim deserves a closer look. The creator says retatrutide helps people "hold onto muscle" not because of any pharmacological property, but because users can still eat, and therefore consume enough protein. This is actually a reasonable read of the available data. No published trial has shown retatrutide to be pharmacologically muscle-sparing in a way that goes beyond adequate protein intake. That is a fair and grounded point, and credit where it is due: many creators sensationalize lean mass preservation on GLP-1 drugs without acknowledging that protein intake and resistance training are the actual drivers. Where the video falls short is the food noise framing. Saying retatrutide "doesn't really optimize its food noise" is an odd way to describe a drug that still produces meaningful appetite suppression through GLP-1 agonism. The distinction being drawn is probably about degree, not presence or absence, and that nuance gets lost. The creator also presents these comparisons as established fact when the drugs have not been tested against each other in any published head-to-head study.

What should you actually know?

Retatrutide is not available through any standard or regulated channel in the United States. It completed Phase 2 trials and Phase 3 is ongoing as of early 2025. Anyone claiming to obtain it is sourcing it through unregulated peptide suppliers, where purity, dosing accuracy, and safety are not guaranteed. That context matters enormously before treating this video as a shopping guide. Tirzepatide is FDA-approved as Mounjaro for type 2 diabetes and as Zepbound for weight management. These are not equivalent to compounded versions sold through third parties. If you are losing muscle on tirzepatide, the solution is not to switch to an unapproved experimental drug. It is to eat adequate protein, do resistance training, and talk to a clinician. The comparative framing in this video, while not wildly inaccurate at the mechanism level, could lead viewers to seek out unregulated substances based on incomplete information.